Drug Trial Radar · NCT05893537
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
100
Actual
Start
Jun 16, 2023
Primary completion
Mar 4, 2025
Study completion Mar 28, 2025
Sponsor
- Lead sponsor
- Cognition TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
Conditions
- Age-Related Macular Degeneration
Interventions
Active Comparator CT1812Drug
123 participants will receive a single daily dose of CT1812 (200 mg)
Placebo ComparatorDrug
123 participants will receive a single daily dose of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye.Time frame: Baseline through Week 104
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Phoenix Retina Associates
Phoenix, Arizona
Retinal Consultants Medical Group
Sacramento, California
Bay Area Retina Associates
Walnut Creek, California
Advanced Research
Deerfield Beach, Florida
Rand Eye Institute
Deerfield Beach, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
Center for Retina and Macular Disease
Winter Haven, Florida
Retina Specialists
Baltimore, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
NJ Retina
Edison, New Jersey
Long Island Vitreoretinal Consultants
Great Neck, New York
North Carolina Retina Associates
Wake Forest, North Carolina
Verum Research LLC
Eugene, Oregon
Erie Retina Research, LLC
Erie, Pennsylvania
Tennessee Retina, PC
Nashville, Tennessee
Austin Clinical Research, LLC
Austin, Texas
Star Vision Consultants
Burleson, Texas
Texas Retina Associates
Fort Worth, Texas
Retina Consultants of Texas
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.